Anixa Biosciences begins patient recruitment for Phase I breast cancer vaccine trial

Anixa Biosciences Inc

Patient recruitment commenced Oct 1, 2021 for a preventative breast cancer vaccine developed with Cleveland Clinic and DoD.
Phase I open-label, dose-escalation trial in triple-negative breast cancer patients at high risk of recurrence.
Estimated 18–24 participants; trial expected to take approximately one year to complete.
Vaccine targets alpha-lactalbumin; details at ClinicalTrials.gov identifier NCT04674306.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.